EFG
NRXP icon

Ethos Financial Group’s NRX Pharmaceuticals NRXP Stock Holding History

Ethos Financial Group’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.4K Hold
15,900
– – ﹤0.01% 624
2026
Q1 		$33.9K Buy
15,900
+4,000
+34% +$8.07K ﹤0.01% 531
2025
Q4 		$32.2K Hold
11,900
– – ﹤0.01% 520
2025
Q3 		$39.3K Buy
+11,900
New +$34.1K ﹤0.01% 495

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ethos Financial Group's NRXP Position: Q2 2026 in Review

Ethos Financial Group held its NRX Pharmaceuticals (NRXP) position steady in Q2 2026 at 15,900 shares worth $51.4K. The position accounts for ﹤0.01% of the portfolio, ranked #624.

Ethos Financial Group first reported a position in NRXP in Q3 2025 and has held it in 4 quarters since. 47 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

  • Ethos Financial Group held 15,900 shares of NRX Pharmaceuticals worth $51.4K as of Q2 2026.
  • Ethos Financial Group left its NRX Pharmaceuticals share count unchanged in Q2 2026.
  • NRX Pharmaceuticals made up ﹤0.01% of Ethos Financial Group's portfolio in Q2 2026, its #624 holding.
  • Ethos Financial Group first reported a position in NRX Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 47 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Ethos Financial Group's 13F filing for Q2 2026, filed 7 Aug 2026.